Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLSP-1025 in Solid Tumors with p53 R175H Mutation
NCT06778863Phase 1Recruiting
- Sponsor
- Clasp Therapeutics
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLSP-1025 in solid tumor (advanced stage), solid tumor, metastatic solid tumor and 8 more, sponsored by Clasp Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
CLSP-1025
03
Conditions
solid tumor (advanced stage)solid tumormetastatic solid tumorcolorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06778863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778863.